Teva nabs FDA approval for Cozaar, Hyzaar; GSK Consumer Healthcare plots Indian investment;

@FiercePharma:Sanofi lays off 400 more U.S. sales reps. Article | | Follow @FiercePharma

> Teva Pharmaceutical Industries has won U.S. approval for its generic versions of Merck's blockbuster blood-pressure drugs Cozaar and Hyzaar. Release

> GlaxoSmithKline Consumer Healthcare will invest more than 2.7 billion rupees (about $60 million) in its Indian operations over the next three years, the Economic Times reported. Report

> Adding to evidence that the acne drug  Accutane (isotretinoin) may lead to bowel disease in some users, a study finds that patients on the medication were four times more likely to develop ulcerative colitis within a year. Report

> Roche's Genentech is just weeks away from starting to ramp up production at its $400 million campus in Hillsboro, Oregon. Report

> GlaxoSmithKline has launched new TV spots for Lovaza, a prescription omega-3 fish oil capsule indicated for the lowering of very high triglyceride levels. Report

> Eli Lilly says U.S. regulators are still reviewing its application for an additional use of the antidepressant Cymbalta for chronic pain. Report

> Paladin Labs says Health Canada has approved Seasonique, a birth-control pill manufactured by a Teva Pharmaceutical Industries unit. Report

> Valeant Pharmaceuticals sold $400 million of senior unsecured notes in a private placement, $50 million more than the originally planned $350 million issue. Report

Biotech News

 @FierceBiotech: Explosion of cancer drug trials spurs a new approach. Article  | Follow @FierceBiotech

 @JohnCFierce: Tengion is looking for $35M out of an IPO this week. The strategy: Aim real low and keep your fingers crossed. Article | Follow @JohnCFierce

> Achaogen raises $56 million for antibiotic work. Report

> Generex sues TheStreet, Feuerstein for $250 million. Item

> Michigan biotech plan brings in 250 jobs. Story

> Alimera files $87 million IPO. Article

Medical Device News

> Medtronic to appeal CoreValve jury verdict. Story

> Boston Scientific's feud with former sales rep heats up. Item

> Judge delays decision on Guidant-Justice settlement after plaintiffs cry foul. Report

> Edwards Lifesciences gets FDA warning letter for reporting delay. Article

And Finally... An analysis of dietary data from more than 400,000 men and women found only a weak association between high fruit and vegetable intake and reduced overall cancer risk. Report